JP2017520513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520513A5 JP2017520513A5 JP2016564605A JP2016564605A JP2017520513A5 JP 2017520513 A5 JP2017520513 A5 JP 2017520513A5 JP 2016564605 A JP2016564605 A JP 2016564605A JP 2016564605 A JP2016564605 A JP 2016564605A JP 2017520513 A5 JP2017520513 A5 JP 2017520513A5
- Authority
- JP
- Japan
- Prior art keywords
- improving agent
- agent according
- function improving
- day
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 21
- 230000007659 motor function Effects 0.000 claims 14
- 230000003920 cognitive function Effects 0.000 claims 11
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 8
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 claims 6
- 229960001284 citicoline Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 239000004129 EU approved improving agent Substances 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461986502P | 2014-04-30 | 2014-04-30 | |
| US61/986,502 | 2014-04-30 | ||
| PCT/IB2015/053178 WO2015166463A1 (en) | 2014-04-30 | 2015-04-30 | Administration of citicoline to improve cognitive performance, attentional performance, and motor function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017520513A JP2017520513A (ja) | 2017-07-27 |
| JP2017520513A5 true JP2017520513A5 (enExample) | 2018-03-08 |
| JP6584430B2 JP6584430B2 (ja) | 2019-10-02 |
Family
ID=54358252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564605A Active JP6584430B2 (ja) | 2014-04-30 | 2015-04-30 | 認知パフォーマンス、注意パフォーマンス、及び運動機能を改善するためのシチコリン投与 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11583546B2 (enExample) |
| EP (1) | EP3137067B1 (enExample) |
| JP (1) | JP6584430B2 (enExample) |
| AU (1) | AU2015254865B2 (enExample) |
| CA (1) | CA2947252C (enExample) |
| ES (1) | ES2915909T3 (enExample) |
| PL (1) | PL3137067T3 (enExample) |
| WO (1) | WO2015166463A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
| JP6584430B2 (ja) | 2014-04-30 | 2019-10-02 | 協和発酵バイオ株式会社 | 認知パフォーマンス、注意パフォーマンス、及び運動機能を改善するためのシチコリン投与 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020198172A1 (en) * | 1997-12-01 | 2002-12-26 | Sandage Bobby W. | Method of treating motor neuron diseases and demyelinating diseases with citicoline |
| US20070004670A1 (en) * | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| US20030114415A1 (en) * | 2001-12-14 | 2003-06-19 | Wurtman Richard J. | Compositions and methods for treating and preventing memory impairment using citicoline |
| CA2517290A1 (en) * | 2003-02-26 | 2004-09-10 | Kyowa Hakko Kogyo Co., Ltd. | Muscle-building agent and preventive or remedy for muscle weakening |
| US20070248696A1 (en) * | 2006-04-25 | 2007-10-25 | Mind Sports Nutrition Inc. | Composition and method for enhancing neuromuscular facilitation and cognitive functions |
| US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
| US20100041620A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods for improving frontal brain bioenergetic metabolism |
| NZ707081A (en) * | 2012-10-30 | 2019-03-29 | Kyowa Hakko Bio Co Ltd | Agent for preventing or improving decline in brain function |
| US9883831B1 (en) * | 2014-01-30 | 2018-02-06 | Texas Health Biomedical Advancement Center, Inc. | Digital medical evaluation and testing on a touch screen device |
| JP6584430B2 (ja) | 2014-04-30 | 2019-10-02 | 協和発酵バイオ株式会社 | 認知パフォーマンス、注意パフォーマンス、及び運動機能を改善するためのシチコリン投与 |
-
2015
- 2015-04-30 JP JP2016564605A patent/JP6584430B2/ja active Active
- 2015-04-30 CA CA2947252A patent/CA2947252C/en active Active
- 2015-04-30 AU AU2015254865A patent/AU2015254865B2/en active Active
- 2015-04-30 WO PCT/IB2015/053178 patent/WO2015166463A1/en not_active Ceased
- 2015-04-30 EP EP15786597.3A patent/EP3137067B1/en active Active
- 2015-04-30 PL PL15786597T patent/PL3137067T3/pl unknown
- 2015-04-30 US US15/307,411 patent/US11583546B2/en active Active
- 2015-04-30 ES ES15786597T patent/ES2915909T3/es active Active
-
2022
- 2022-12-21 US US18/069,325 patent/US12115181B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| BR112015024411A2 (pt) | desaza-purinonas macrocíclicas para o tratamento de infeções virais | |
| JP2019068829A5 (enExample) | ||
| JP2016034978A5 (enExample) | ||
| BR112018000749A2 (pt) | métodos e composições para a diagnose e para o tratamento de adrenoleucodistrofia | |
| BR112017005111A2 (pt) | compostos, composição farmacêutica, usos de um composto ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de um hospedeiro infectado com um papilomavírus humano, usos de um composto, método para a fabricação de um medicamento destinado ao uso terapêutico para o tratamento de uma infecção por papilomavírus | |
| EP3498279A4 (en) | PHARMACEUTICAL COMPOSITION WITH AMODIAQUIN AND ANTIDIABETIC MEDICINAL PRODUCT AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING DIABETES | |
| JP2016530265A5 (enExample) | ||
| MA41326A (fr) | Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation | |
| EA201891473A1 (ru) | Комбинированная терапия | |
| CL2015002627A1 (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol | |
| JP2015535241A5 (enExample) | ||
| JP2010526884A5 (enExample) | ||
| BRPI0602397C1 (pt) | composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições | |
| JP2019513151A5 (enExample) | ||
| WO2020139163A3 (ru) | Комбинация противовирусных средств | |
| EP2902024A4 (en) | A SYNERGISTIC COMPOSITION OF NITAZOXANIDE AND MEANDAZOL, METHOD FOR THE PRODUCTION THEREOF AND USE OF THIS COMPOSITION FOR THE TREATMENT OF HUMAN PARASITES | |
| Inoue et al. | The MILES trial: the effect of Asian race on outcomes in patients with lymphangioleiomyomatosis | |
| RU2012100120A (ru) | Акарицидная фармацевтическая композиция на основе соли четвертичного фосфония, замещенного динитробензофураксана и ксимедонгидрохлорида | |
| Gandhi et al. | Older age associated with both adherence and renal decline in the PrEP demo project | |
| Marcellin et al. | ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naïve genotype 1 (GT1) patients: 86 | |
| Agarwal et al. | Approaches for enhancement of solubility to improve the absorption and bioavailability of poorly soluble drugs | |
| Baptista et al. | 0329 The shift work and the Burnout syndrome | |
| Nakata et al. | Risk Factors For Stomatitis In Patients With Lymphangioleiomyomatosis During Treatment With Sirolimus: A Multicenter Investigator-Initiated Prospective Study | |
| Reid | Emerging Epidemics |